ALEC Alector, Inc.
USHealthcareAs of 2026-07-10 16:00
Why ALEC matters now
Alector, Inc. (ALEC) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.61 with -1.53% on the session and $178.8M in market capitalization; recent performance reads 1-month -17.06% and YTD +12.18%.
The latest financial table shown here is Q1 2026, with revenue of $1.0M, net income of $-22.9M, and EPS of $-0.21. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -89.1%.
The latest indexable market news headline is "Alector and GSK partnership to end after dementia, Alzheimer's drug failures" from Reuters.
Additional event context on this page matters because analyst consensus is Hold with a median target of $2.00; recent insider activity includes LAVIGNE LOUIS J JR filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
18.64
P/S
10.55
EV/EBITDA
-1.30
DCF Value
$-0.22
FCF Yield
-89.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
-61.2%
Operating Margin
-741.3%
Net Margin
-680.8%
ROE
-295.2%
ROA
-52.3%
ROIC
-65.1%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $1.0M | $-22.9M | $-0.21 |
| Q4 2025 | $6.2M | $-37.3M | $-0.34 |
| FY 2025 | $21.0M | $-142.9M | $-1.39 |
| Q3 2025 | $3.3M | $-34.7M | $-0.34 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$2.00
Target (Median)
$2.00
Target Range
$2.00 - $2.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.59
Alector, Inc. is a clinical-stage biopharmaceutical company dedicated to pioneering new treatments for neurodegenerative disorders. A key program in its pipeline is AL001, a humanized recombinant monoclonal antibody currently undergoing Phase III clinical trials. This investigational therapy targets a range of severe conditions, including frontotemporal dementia, Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). Additionally, AL101 is progressing through Phase I clinical trials for general neurodegenerative diseases, with a specific focus on Alzheimer's and Parkinson's. Further bolstering its Alzheimer's portfolio, Alector is evaluating AL002 in Phase II studies and AL003 in Phase I studies, both aimed at addressing Alzheimer's disease. In earlier-stage development, the company is also developing AL044, which targets the MS4A4A gene, identified as a risk factor for Alzheimer's disease. Alector has forged key partnerships to advance its mission. It collaborates with Adimab, LLC on antibody research and development. Furthermore, a significant strategic alliance with GlaxoSmithKline plc (GSK) focuses on the joint development and commercialization of monoclonal antibodies, specifically AL001 and AL101, for neurodegenerative conditions. Established in 2013, Alector's headquarters are located in South San Francisco, California.